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Cost effectiveness of aortic valve 
therapies: a systematic review of 
the literature
Suzanne Battaglia(1), Walter Mazzucco(2), Walter Ricciardi(2)
Background: we performed a systematic review on the cost effectiveness of transcatheter aortic valve 
implantation (TaVI) to standard aortic valve replacement and medical management in high-risk elderly 
patients with severe aortic stenosis. 
MeThods: in accordance with Preferred reporting Items for systematic reviews and Meta-analyses, a 
systematic review on current literature for cost-effectiveness of TaVI, standard aortic valve replacement, 
and medical management for elderly patients with high-risk severe aortic stenosis was performed. 
Incremental cost effectiveness ratio is used to measure effectiveness through life years gained or quality 
adjusted life years. drummond checklist was used to further assess the quality of the included studies. 
resulTs: the systematic literature search identified 4 primary publications (derived from 52 
citations) that fulfilled the inclusion criteria. Tremendous discrepancy in incremental cost 
effectiveness ratio is demonstrated with operable patients similar to cohort a of the ParTner 
trial (€ 749 416 and € 39 577). Inoperable patients similar to cohort B of the ParTner trial suggest 
notable differences in favour for transcatheter aortic valve implantation with an increase in quality 
adjusted life years (0.06 versus 1.6, respectively). With lifetime horizon to transcatheter aortic valve 
implantation there is a more comparable incremental cost effectiveness ratio in the literature (€ 38 260 
and € 37 432). lowest incremental cost effectiveness ratio witnessed in the technical inoperable group 
at € 26 482. lifetime horizon of 10 years with transcatheter aortic valve implantation differ (€ 39 388 
versus € 19 947).  overall, a review of the literature suggests TaVI usage in patients for severe aortic 
stenosis whom are not eligible for surgery. all the studies were overall judged of medium-high quality.
conclusIons: transcatheter aortic valve replacement is more cost effective with a lifetime horizon for 
the treatment of patients with high-risk aortic stenosis compared with medical management considering 
those ineligible for standard aortic valve replacement. Further cost effectiveness research is needed in 
the stratifications of patient risk and patient co-morbidities for those candidates eligible for surgery. 
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InTroducTIon
Aortic stenosis (AS) is one of the most 
frequently encountered cardiovascular diseases 
and has a substantial socioeconomic burden; 
without valve replacement, symptomatic patients 
with severe AS have a mortality >70% within a 
few years of symptom onset [1]. In the coming 
decades, there will be a tremendous aging of 
the population in developed countries with a 
unique increase of inhabitants older than 80 
years [2]. Depending on patient risk severity and 
operability, medical management for high risk 
patients with AS is performed. In spite of this, 
aortic valve replacement (AVR) has been proven 
to significantly prolong life expectancy and 
improve quality of life. Although AVR is regarded 
to be the mainstay for improved survival and 
symptom relief, not all patients, especially the 
elderly, are able to profit from this technique [2]. 
Transcatheter aortic valve implantation (TAVI) is 
rapidly gaining acceptance as a viable therapy 
for severe aortic stenosis for patients deemed 
at prohibitive or excessive surgical risk [3]. 
In 2002 Criber et al performed the first TAVI 
for patients with inoperable aortic stenosis 
[4]. As of June 2010, approximately 20 000 
procedures have been performed worldwide 
with over 425 interventional centres, and this 
number experiences exponential growth [2, 
5]. At present, two different TAVI valves have 
been accepted into the European market: the 
SAPIEN® valve of Edwards Lifesciences and 
CoreValve® of Medtronic. Presently, only one 
randomized control trial studying the safety and 
efficacy of TAVI was published in September 
2010 with an additional analysis published in 
June 2011: Placement of AoRtic TraNscathetER 
valve (PARTNER I and II). Although patient 
selection, operator skills, and technology have 
improved, all previous TAVI studies have been 
observational registries, without standardization 
or endpoint definitions, without formal clinical 
events committees, and without independent 
echo core lab [5].
Health economic analysts have designed 
frameworks to evaluate the economic impact 
and value for improvements in health and 
longevity. This could have important decision 
making implications for usage to be justified 
for long term performance. Given the advanced 
age and multiple co-morbidities conditions that 
characterize patients with high surgical risk 
for surgical valve replacement, the question of 
whether TAVI can provide meaningful health 
benefits to the population at an acceptable cost is 
particularly germane [6]. New technologies into the 
market place are cited to contribute to increasing 
healthcare costs. Therefore, before a technology is 
adopted it is important to understand the clinical 
and economic implications up front, as it is more 
difficult to withdraw from usage once approved. To 
date, there is limited objective evidence measuring 
the cost effectiveness of TAVI compared to SAVR 
and standard medical treatment. 
MeThods
eligibility criteria
The systematic review is based on 
published peer-reviewed full-text reports in 
randomized control trials as well as case 
studies, cohort studies and secondary literature 
from health technology institutes and reports 
from governing bodies. It is in accordance with 
Preferred Reporting Items for Systematic reviews 
and Meta-Analysis (PRISMA), pre-established 
criteria for inclusion and exclusion into this 
review can be found in Table 1 [7]. Additional 
literature searches for clinical effectiveness of 
TAVI and AS along with learning curves and 
operative risk factors were used for a deeper 
comprehensive understanding of the disease 
and not factored into inclusion criteria. 
data collection Process
The literature search was performed in 
MEDLINE, the search strategy consisted of 
vocabulary including titles, abstracts, keywords 
such as “cost effectiveness transcatheter aortic 
valve implantation” or “cost effectiveness 
transcatheter aortic valve replacement”, 
“review” or “systematic review”, and “health 
technology assessment”, and “cost effectiveness 
aortic stenosis”. The search was restricted to 
the English language but not to any specific 
time period. Findings from MEDLINE were last 
update on April 2nd 2012. These searches were 
complemented by searching the reference lists 
of key papers to identify any additional relevant 
studies. No limitations were based on the study 
type. For further searches, Agencies for Health 
Technology Assessment (INAHTA) electronic 
databases, National Institute for Health and 
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Clinical Excellence (NICE) and supplemental 
databases of national governing body Canadian 
Agency for Drug and Technologies in Health 
(CADTH) were reviewed. Selection of literature 
was constructed in two ways: an initial screening 
of the literature search by title, abstract and 
keywords followed by full-text publications, 
health technology assessments, and reports. 
The rational for any exclusion criteria of data 
in the literature search is mainly due to lack of 
relevance to cost-effectiveness information. 
Quality assessment 
Drummond checklist was used to further 
evaluate the quality of the studies included in 
the systematic review [8]. The checklist was 
developed to assess the quality of an economic 
evaluation considering the following sections: 
study design, data collection, analysis and 
interpretation of results. All of the 35 items 
were explored by two independent reviewers 
(S.B., W.M.) per each included study. 
resulTs
results of literature search
For the transparent reporting of this 
systematic review, the PRISMA statement 
consists of a 27-item checklist and a four phase 
flow diagram [7]. As illustrated in the flow 
chart in Figure 1 the original literature search 
identified a total of 52 citations (whereby 10 
cost effectiveness TAVI/TAVR and 42 cost 
effectiveness aortic stenosis). Based on the 
screening of titles and abstracts 38 citations were 
excluded from the review and 13 potentially 
relevant publications were retrieved for full text 
screening. An additional 13 potentially relevant 
reports were retrieved through hand searching 
the reference list papers, 26 underwent a 
detailed full-text screening, yielding 4 [1, 4, 6, 
9] primary publications for TAVI, SAVR, and 
medical management of AS. 
Most of the data available with a cost 
effectiveness search tended to be prior to the 
PARTNER trial and mainly cost minimization 
analysis or cost of illness in specified hospital 
settings. Since the publication of PARTNER trial 
in September 2010, the 4 primary publications for 
this systematic review are in reference to select 
patient cohorts from this study. As highlighted 
by Leon et al., the key study characteristics 
and patient types for the PARTNER trial are 
described in Table 2. Most included studies were 
recently published with publication year from 
2007 and as recent as March 2012. 
Quality of the included studies
Table 3 reports qualitative evaluation 
assigned to each included study, according 
to the 35 items exploring study design, data 
collection and analysis and interpretation of 
results. All studies presented lack in the data 
collection section and in part explanation of 
analysis and interpretation of results, being 
adherent to almost all of the remaining items 
explored. Study design items were adherent for 
all of the studies, except for the choice of form 
of economic evaluation justification in relation 
to the questions addressed in Neyt et al. and 
Gada et al. studies [1, 9]. 
On the contrary, some deficiencies have 
been highlighted referring to data collection 
section, details of the design and results of study 
TABLE 1
IncLusIon And ExcLusIon crITErIA for puBLIcATIons
chArAcTErIsTIc crITErIA
Publication type
Peer-reviewed full-text publications that report cost-effectiveness outcomes, 
systematic reviews, publications from health technology institutes, and government 
agencies. Papers presented at conferences were excluded due to restricted access
Language English
Intervention Transcatheter aortic valve implantation (TAVI)
Study characteristics Cost-effectiveness studies, including case reports
Economic/Health Outcome Cost effectiveness, Quality adjusted life years (QALY) and life years gained (LYG)
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effectiveness, were not clearly given by Gada et 
al. [1]. The inconsistency for items 10 and from 
13 to 19 documented some methodological 
limits for all of the four studies [1, 6, 9, 10]. 
Lastly, for items included in the analysis 
and interpretation of results, all studies stated a 
discounted rate but inconsistency for justifications of 
rate used and source of data for sensitivity analysis 
are not provided by Watt et al and Reynolds et al. 
[6, 10]. According to Drummond’s checklist, studies 
were judged to be of medium-high quality, giving 
consistency to the systematic review. 
TABLE 2
pArTnEr pATIEnT cohorTs (pIvoTAL And comBInEd AccEss sTudy)
cohorT A cohorT B
• High risk patients with an estimated operative 
mortality risk of at least 10% by the STS score, 
or at least 15% due to other severe problems not 
included in the STS score
• Patients were randomised to transfemoral 
or transapical TAVI depending on whether or 
not transfemoral access was possible versus 
the classical surgical treatment (aortic valve 
replacement - AVR). In the analysis of the primary 
endpoint of the trial (all-cause mortality) both TAVI 
variants together were compared with surgery 
• Patients considered as inoperable by at least two 
heart surgeons either due to anatomical factors 
(thoracic wall malformation, repeated previous 
thoracic surgeries, significant aortic calcification - so 
called porcelain aorta, sequelae of radiotherapy) or 
due to concomitant severe medical conditions 
• Patients with the possibility of a transfemoral access 
were randomized to transfemoral TAVI versus a 
standard therapy which, in addition to medication, 
generally involved balloon aortic valvuloplasty, a 
technique where the narrowed aortic valve is dilated 
with a balloon 
Reference: Belgian Healthcare Knowledge Centre [9]
fIgurE 1
fLow of InformATIon for sysTEmATIc rEvIEw
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TABLE 3
QuALITy of IncLudEd sTudy
rEfErEE’s chEckLIsT sTudy Id
ITEm nEyT 2011
wATT 
2012
gAdA 
2012
rEynoLds 
2012
St
ud
y 
de
si
gn
(I) The research question is stated Y Y Y Y
(2) The economic importance of the research question is stated Y Y Y Y
(3) The viewpoint(s) of the analysis are clearly stated and justified Y Y Y Y
(4) The rationale for choosing the alternative programmes or interventions 
compared is stated Y Y Y Y
(5) The alternatives being compared are clearly described Y Y Y Y
(6) The form of economic evaluation used is stated Y Y Y Y
(7) The choice of form of economic evaluation is justified in relation to the 
questions addressed NC
1 Y NC5 Y
D
at
a 
co
lle
ct
io
n
(8) The source(s) of effectiveness estimates used are stated Y Y Y Y
(9) Details of the design and results of effectiveness study are given (if 
based on a single study) Y
2 Y NC Y
(10) Details of the method of synthesis or meta-analysis of estimates are 
given (overview) N NC
4 NC6 N7
(11) The primary outcome measure(s) for the economic evaluation are 
clearly stated Y Y Y Y
(12) Methods to value health states and other benefits are stated Y Y Y Y
(13) Details of the subjects from whom valuations were obtained are given NC NC NC Y
(14) Productivity changes (if included) are reported separately N N N N
(15) The relevance of productivity changes to the study question is 
discussed N N N N
(16) Quantities of resources are reported separately from their unit costs N N N Y
(17) Methods for the estimation of quantities and unit costs are described NC3 N N NC8
(18) Currency and price data are recorded Y Y Y Y
(19) Details of currency of price adjustments for inflation or currency 
conversion are given NC N N N
(20) Details of any model used are given Y Y Y Y
(21) The choice of model used and the key parameters on which it is based 
are justified Y Y Y Y
A
na
ly
si
s 
an
d 
in
te
rp
re
ta
ti
on
 o
f r
es
ul
ts
(22) Time horizon of costs and benefits is stated Y Y Y Y
(23) The discount rate(s) is stated Y Y Y Y
(24) The choice of rate(s) is justified Y N N N
(25) An explanation is given if costs or benefits are not discounted N N N N
(26) Details of statistical tests and confidence intervals are given for 
stochastic data Y Y Y Y
(27) The approach to sensitivity analysis is given Y Y Y Y
(28) The choice of variables for sensitivity analysis is justified Y N Y N
(29) The ranges over which the variables are varied are stated Y Y Y Y
(30) Relevant alternatives are compared Y Y Y Y
(31) Incremental analysis is reported Y Y Y Y
(32) Major outcomes are presented in a disaggregated as well as 
aggregated form Y Y Y Y
(33) The answer to the study question is given Y Y Y Y
(34) Conclusions follow from the data reported Y Y Y Y
(35) Conclusions are accompanied by the appropriate caveats Y Y Y Y
Legend: Y= yes; N= not; NC= not clear
1 HTA although mainly clinical & economic evaluations
2 Based on PARTNER trial and Belgian TAVI Data
3 Section 6.1.1 redirects to 4.2 and 4.3: no specifics
4 Literature review - no methods to review discussed
5 Decision analytic model used - Markov Model
6 Published reports & data used from registries (Table 2)
7 Based on PARTNER Trial
8 TAVR procedure costs - average acquisition costs
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synthesis of results
The literature review conducted by Gada 
et al. in patients with high surgical risk 
TAVI, whom AVR is the current procedure 
of choice, appears to provide similar surgical 
outcomes for those of AVR [1]. The costs 
for TAVI and AVR are higher than medical 
management, although the outcomes are also 
superior to those of medical management. 
The cost-effectiveness ratio of TAVI and 
AVR was € 29 988/QALYs and € 29 475/
QALYs, respectively [1]. An additional gain of 
0.06 QALYs with the use of TAVI over AVR 
is observed. The cost of TAVI was greater 
than that of AVR (€ 44 649 vs. € 42 275), 
yielding an ICER of € 39 577/QALYs [1]. A 
threshold analysis is implemented suggesting 
the variation in net monetary benefit is 
influenced mainly in relation to TAVI. The 
net monetary benefit from AVR exceeded 
TAVI at a threshold TAVI cost of € 41 356 
[1]. Using the PARTNER costs with transition 
probabilities and mortality rates outlined in 
the Gada et al. review the ICER of TAVI is 
€ 24 003/QALYs [1]. As illustrated in Table 4, 
observations in the PARTNER trial (Cohort A) 
analyses the difference in lifetime costs were 
minimal and a small net health benefit using 
TAVI compared to AVR is demonstrated, the 
differences in utilities were not noted. 
According to the literature review 
conducted by Reynolds et al. the results were 
relatively insensitive to changes in the discount 
rate or the assumed acquisition cost of the study 
device or the exclusion of costs associated with 
balloon valvuloplasty procedures from the 
control group [6]. The estimated difference in 
discounted lifetime medical care costs of € 60 
859 and a gain in discounted life expectancy of 
1.6 years resulted in an ICER of € 38 260 [6]. 
In reference to Table 4, with a decrease in time 
horizon from lifetime to 10 years and 5 years 
there is an increase ICER from € 38 260 to € 
39 388 and € 43 742, respectively. As the time 
horizon increases so does the QALYs or life years 
(LY) expressed to suggest an overall increase 
with TAVI than when compared to the control 
group. However, due to lack of standardization 
amongst cost effectiveness reviews it can be 
misleading. Conceivably measurement for 
effectiveness in QALYs presents no assumed 
improvement over time in the baseline utility 
scores for either group, as a result the ICER for 
TAVI became less favourable at approximately 
€ 63 191 [6]. Reynolds et al. suggest that 
although expert panels recommend the use 
of QALYs as a standard effectiveness measure 
in health economic analysis this guidance 
is not universally accepted both because of 
imprecision in the methods used to estimate 
QALYs and because there is both philosophical 
and political opposition to the notion that life-
years for one group might be valued differently 
than life-years for another group due to age, 
disability or chronic health problems [6]. 
Furthermore in the literature review 
conducted by Watt et al. a cost effectiveness 
model is used to compare the costs and 
benefits over a 10 year time horizon of 
medical management versus TAVI in patients 
with inoperable aortic stenosis [4]. Similarly, 
the results presented in the PARTNER 
trial (Cohort B) are implemented into the 
cost effectiveness model. To note, 83% of 
individuals in the medical management 
arm were assumed to receive a balloon 
aortic valvuloplasty (BAV) procedure and 
all incurred the costs of pharmacological 
treatment [4]. In comparison to medical 
management, individuals in the TAVI arm 
incurred an additional 1.56 QALY’s at 10 year 
cost per patient of € 30 296 suggesting a base 
case ICER of € 19 467 per QALY gained [4]. 
As observed in the PARTNER trial (Cohort 
B), using pooled input parameters, there is 
an additional 1.54 QALY’s at 10 year cost 
per patient of € 30 777 suggesting a base 
case ICER of € 19 947 per QALY gained. The 
majority of TAVI related costs correspond to 
the initial implant operation (€ 22 846) or 
perioperative intensive care unit (ICU) care 
(€ 3 006), although saving are avoided in 
terms of BAV procedures (-€ 2885) [4]. The 
overall total procedure costs are the lowest 
amongst the reviews and possibly this can 
partially account for the significantly lower 
ICER relative to other centres. 
The fourth principle publication used for this 
systematic review is the TAVI Health Technology 
Assessment completed by the Belgian Health 
Care Knowledge Centre, referenced as Belgian 
HTA report [9] for costs and reimbursements in 
Belgium. In reference to Table 5, reviewing the 
base case results and various scenario analyses, 
the cost effectiveness calculated for Cohort A 
suggests a substantial incremental cost for TAVI 
versus AVR. The average ICER is about € 750 000 
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TABLE 4
cosT EffEcTIvEnEss LITErATurE rEvIEws for TAvI TrEATmEnT
compArEd To Avr And mEdIcAL mAnAgEmEnT
puBLIcATIon 
(yEAr)
TypE of 
EconomIc 
EvALuATIon 
And TImE 
horIzon
pErspEcTIvE 
And counTry
popuLATIon /
sAmpLE TrEATmEnT
mEAsurE of 
ouTcomE rEsuLTs
gAdA ET AL. 
(2012)
Cost Effectiveness 
Analysis
Time Horizon:
Lifetime
Economic and Clinical
USA 10 000 simulations
Reference case
(operable AVR 
candidates)
TAVI
AVR 
ICER (€/QALY)
Direct Medical Costs: 
Inpatient treatment 
costs (DRG), 
TAVI and AVR annual 
follow-up plus 1 
outpatient visit. 
Medical management 
annual costs post 
diagnosis.
Base Case: 
€ 39 577 
+0.06
PARTNER costs
TAVI
AVR
PARTNER Costs:
€ 24 003 
+0.06
Alternative Scenario
PARTNER (Cohort A) 
TAVI
AVR
Alternative Scenario:
NA
+0.01
Sensitivity Analysis: 
MonteCarlo 
simulation 
(probabilistic) - Cost 
effectiveness plane 
less robust with AVR 
when compared to 
TAVI. 
Indirect:
Not considered
rEynoLds ET 
AL.
(2012)
Cost Effectiveness 
Analysis
Time Horizon:
Lifetime, 10 years, 
and 5 years
Economic and
Clinical
USA
TAVR 
(n=179)
Standard Therapy 
(n=179)
PARTNER 
(Cohort B - lifetime) 
TAVI
MM
(€/LYG)
Direct Medical Costs:
Medical Management 
costs from hospital 
billing.
TAVI costs for in-
hospital treatment.
Follow-up hospital 
care costs (MS-DRG)
Rehabilitation facility 
costs included when 
available. Physician 
fees included for 
TAVI.
Base Case: (lifetime 
horizon) 
€ 38 260 
+1.59
PARTNER 
(Cohort B - 10 years) 
TAVI
MM
Base Case: 
(10 year horizon)
€ 39 388 
+1.52
Base Case: 
(5 years) 
€ 43 742 
+1.27
Indirect:
Not Considered
Sensitivity Analysis:
Sensitivity analysis 
performed but type 
not stated.
€ 63 191 ICER
PARTNER 
(Cohort B - 5 years)
TAVI
MM
 wATT ET AL.
(2012)
Cost Effectiveness 
Analysis/ Cost 
Benefit Analysis
Time Horizon:
30 days, 10 years
Economic and Clinical
UK/Germany
2 interlinked Markov 
models used: 
short term - 30 days
 long term - 10 years.
Number of cycles not 
stated.
Base Case 
TAVI
MM
ICER (€/QALY)
Direct Medical Costs:
Drug costs, treatment 
specific costs, all 
procedure and device 
costs for TAVI taken 
from costing study, 
Base Case: € 19 467 
+1.56
Alternative Scenario:
€ 19 947 
+1.54
Sensitivity Analysis: 
MonteCarlo 
simulation 
(probabilistic) 
and deterministic 
analysis. Robust 
to changes in 
hospitalization costs 
and adverse events, 
very sensitive to 
changes in short-
term treatment effect 
and cost of initial 
operation.
Indirect:
Not ConsideredAlternative Scenario
PARTNER (Cohort B) 
TAVI
MM
Note: XE Universal Currency Converter (April 2 2012): 1 Euro = 0.83 GBP, 1 Euro = 1.33 USD
Gada et al. EuroSCORE patient risk of TAVI & AVR > 15%. STS patient risk of TAVI & AVR > 10%, discounted at 5%, lifetime horizon
Reynolds et al. New York Heart Association functional class ≥ 2, high surgical risk based on STS, costs discounted at 3%, EQ-5D 
measurement for QALY ( *QALYs or LY)
Watt et al. EuroSCORE patient risk of TAVI & AVR > 15%. STS patient risk of TAVI & AVR > 10%, discounted at 3.5%, time horizon 10 years
e 8 8 7 2 - 7
SyStemat i c  r ev i ewS  and  meta -  and  pooled  analySeS
epidemiology Biostatistics and public Health - 2013, volume 10, number 4
coSt effectiveneSS of aortic valve tHerapy
per life years gained (LYG) or per QALY gained 
[9]. Even with a decrease in the TAVI device 
cost from € 18 000 to € 10 000 the average ICER 
remains above € 450 000 per LYG or QALY 
gained [9]. The cost effectiveness calculated for 
Cohort B suggests with a lifetime treatment effect 
the average ICER is about € 37 400 per QALY. 
When taking into account a mortality time horizon 
scenario of 3 years, the average ICER increases to 
€ 71 573 per QALY. It is suggested that the net 
monetary health costs contribute largely to the 
cost of the device at € 18 000. Lowering the TAVI 
device cost to € 10 000 brings down the ICER to 
roughly € 30 000 per QALY and small increments 
with little impact are illustrated with an increase 
in additional fees. 
As stated in Table 6, in the Pivotal study 
(PARTNER I), the Belgian HTA report suggests 
a similar ICER with a lifetime horizon as 
observed by Reynolds et al. at approximately € 
38 000. With additional patients in the continued 
access study (PARTNER II) it did not show as 
favourable findings with an increased lifetime 
ICER of € 44 932. Through stratification of the 
data in inoperable patients of Cohort B there is 
a demonstrative difference in ICER. Although 
a reduction in mortality is observed in both 
subgroups, those inoperable patients due to 
technical reasons suggest the most advantageous 
ICER of € 26 482 per QALY vs. the non-technical 
group at € 42 285 per QALY [9].
dIscussIon
From an economic perspective, comparing 
the Belgian HTA report to Gada et al. suggests 
significant differences in cost effectiveness 
outcomes regardless of device costs. With a 
10 year lifetime horizon, the literature review 
conducted by Gada et al. suggests a reference 
case ICER of € 39 577 compared to Belgian HTA 
report [9] outcome of € 749 416 for patients 
of high-risk severe AS who are still operable. 
Furthermore, factoring a scenario analysis with 
a reduced TAVI cost from € 18 000 to € 10 000 
the data continues to suggest a drastic difference 
in ICER at € 455 461. Using the scenario results 
from PARTNER costs in Gada et al., further 
illustrates a tremendous discrepancy with an 
ICER of € 24 012. Limited information is provided 
by the Belgian HTA report on the summation 
of costs. Health economic evaluations should 
be designed with more costs transparency to 
accurately compare consumption of resources. 
At this time further investigation is needed to 
clarify significant differences. 
In the same way for high-risk patients 
who are inoperable due to anatomical factors, 
significant aortic calcification, or medical 
conditions the base case results between Watt et 
al. and Reynolds et al. suggest an ICER with a € 
20 000 difference at a 10 year time horizon. Watt 
et al. ICER of € 19 467 or PARTNER (Cohort 
B) of € 19 947 is significantly less compared 
to the ICER results demonstrated with the 
Reynolds et al. PARTNER (Cohort B) at an ICER 
of € 39 388 with the intent of a similar patient 
population. Similar to above, bearing in mind 
factors attributed to the cost of TAVI medical 
device and the contributions to the total costs of 
the procedure will vary, all direct medical and 
indirect costs relevant to the perspective chosen 
for the study should be clearly defined in unit 
quantities and prices for comparability.
Less widespread are the comparison of 
ICER’s at lifetime horizon for patients considered 
inoperable between Belgian HTA reports with 
an ICER of € 37 432 to Reynolds et al. lifetime 
horizon with an ICER of € 38 260. In both cases, 
with a reduced time horizon scenario of 3 years 
and 5 years this ICER increases to € 71 573 in 
the Belgian HTA report with a parallel increase 
of € 43 742 amongst the Reynolds et al. review 
respectively. The choice of time horizon used 
in these economic analysis’s are reflected in 
the respective increases in ICER, fundamentally 
further consideration to the age and average life 
expectancy of the patient population studied 
should be taken into account for health policy 
decisions. The Belgian HTA report continues to 
illustrate with inoperable (Cohort B) patients’ 
economic outcomes with reduced device costs 
from € 18 000 to € 10 000 and factoring 
variable inclusive TAVI device fees. Savings are 
demonstrated by lowering the cost per device 
resulting in an ICER close to € 30 000 and 
after initial rise of device fees of € 500 minimal 
impact is attributed to further increases in 
device fees. When TAVI is compared to medical 
management the incremental cost effectiveness 
over lifetime horizon is more advantageous 
and likely recommended. Short term survival 
can represent a major drawback to the cost 
effectiveness of TAVI, however if economic 
evaluations can be reproduced transparently 
different viewpoints and perspectives may 
influence policy decisions. 
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TABLE 5
BELgIAn hTA rEporT, BAsE cAsE rEsuLT And scEnArIo AnALysEs for TAvI
puBLIcATIon 
(yEAr)
TypE of 
EconomIc 
EvALuATIon 
And TImE 
horIzon
pErspEcTIvE 
And counTry
popuLATIon /
sAmpLE TrEATmEnT
mEAsurE of 
ouTcomE rEsuLTs
BELgIAn 
hEALTh cArE 
knowLEdgE 
cEnTrE
(2011)
Health 
Technology 
Assessment
Cost 
effectiveness 
analysis, Cost 
utility analysis
Time Horizon:
Lifetime, 3 years
Economic, Clinical
Belgium
1000 TAVI eligible 
patients
Markov 
model simulation
Cohort A 
TAVI € 18 000
Base case 
(lifetime horizon)
ICER (€/LYG)
ICER (€/QALY)
Direct Medical 
Costs: 
From perspective 
of healthcare 
payer. 
TAVI - Treatment 
costs during 
hospitalization and 
ambulatory costs, 
device costs.
AVR – 
hospitalization 
costs, no 
ambulatory costs.
Cohort A 
TAVI € 18 000
€ 759 072 or 
€ 749 416
+0.03
(LYG and QALY)
Cohort A 
TAVI € 10 000
Scenario analysis
(3 year horizon) 
Cohort A 
TAVI € 10 000
€ 461 360 or 
€ 455 461
+0.03 
(LYG and QALY)
Cohort B
Base case
(lifetime horizon)
Cohort B
Base case
€ 31 856 or 
€ 37 432
+1.16 (LYG)
+0.92 (QALY)
Cohort B 
(3 year horizon)
Cohort B 
€ 68 208
€ 71 573
0.55 (LYG)
0.47 (QALY)
Cohort B 
TAVI € 10 000
Cohort B 
TAVI € 10 000
€ 24 735 or 
€ 29 117
1.16 (LYG)
0.92 (QALY)
TAVI device fee 
€ 500
€30 945 or € 36 368
+1.16 (LYG)
+0.92 (QALY)
TAVI device fee 
€ 1 000
€ 31 400 or € 36 900
+1.16 (LYG)
+0.92 (QALY)
Indirect:
Not considered
Cohort B 
With TAVI device fee 
€ 500
With TAVI device fee 
€ 1 000
Cohort B (base case)
TAVI device fee 
€ 1 500
€ 31 856 or € 37 432
+1.16 (LYG)
+0.92 (QALY)
Sensitivity Analysis:
MonteCarlo 
Simulation 
(probabilistic). 
Cost effectiveness 
plan for Cohort A 
measures life years 
gained vs Cohort 
B measures QALY. 
Cohort B illustrates 
more robust results
Cohort B
(base case)
With TAVI device fee 
€ 1 500
Reference: Belgian Healthcare Knowledge Centre [9]
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The technique of TAVI is a risky procedure 
consequently the learning curve should also 
be considered to clinical outcomes and cost 
effectiveness. The combination of operator 
experience, patient selection, and technological 
advancements can have important implications 
on procedural complications and potentially 
cost effectiveness outcomes. The minimum 
volume of training for each operator to 
eliminate the learning curve is important, 
and further study is required to determine 
the minimum number of yearly procedures 
required to maintain TAVI competency [3]. 
The Belgian HTA report advises to guarantee 
a sufficient workflow TAVI treatment the 
procedure should be limited to 1 or 2 Belgian 
centres [9]. To sustain operator experience, 
minimize procedural complications and impact 
costs of the procedure, future considerations to 
the number of centres undertaking this cardiac 
procedure can be further contemplated. In the 
same way organizational structure and impact 
on how care is delivered warrants further 
discussion (hybrid context vs. operating room) 
when evaluating cost effectiveness. In regards to 
patient selection and stratification, furthermore 
two different methods of predicting the level 
of operative mortality risk are used in the four 
studies included, EuroSCORE and Society of 
Thoracic Surgeons (STS) risk score. A review 
is reasonable for comparability to patient 
selection and stratification across studies. 
Literature suggests, with experience and 
increased procedural acceptance by referring 
physicians and cardiothoracic surgeons, it is 
likely the pendulum will swing from only truly 
inoperable patients to those who are potentially 
otherwise operable albeit at a higher risk [3]. 
Overall, disclosure of information on costs and 
differences in economic evaluations limit the 
making of reliable analysis. Although the four 
studies included in the systematic review are 
of good quality, some deficiencies have been 
documented in the data collection section and 
future studies will need to take better account of 
the items from a methodological point of view. 
This is also necessary to perform economic 
evaluations comparable and scientifically based.
This is a rapidly evolving technology 
amongst the medical community and only 
recently implemented for use in many countries. 
As stated in the PARTNER trial, on the basis 
TABLE 6
sTrATIfIcATIon of dATA wITh ThE BELgIAn hEALThcArE knowLEdgE cEnTrE
pIvoTAL And 
conTInuEd 
AccEss
IncrEmEnTAL 
cosT
IncrEmEnTAL 
EffEcT (Lyg)
IncrEmEnTAL 
EffEcT (QALy) IcEr (€/Lyg) IcEr (€/QALy)
Cohort B - 
Pivotal 
(baseline)
€ 34 590
(€ 29 881 – 
€ 38 631)
1.16
(0.65 – 1.75)
0.92
(-0.29 – 1.90)
€ 31 856
(€ 20 259 – 
€ 51 554)
€ 37 432
Cohort B - 
Combined
€ 33 243
(€ 27 452 – 
€ 37 773)
0.88
(0.39 – 1.41)
0.74
(-0.44 – 1.69)
€ 42 647
(€ 23 655 – 
€ 86 311) € 44 932
TEchnIcAL vs 
non-TEchnIcAL 
InopErABLE 
pATIEnTs
IncrEmEnTAL 
cosT
IncrEmEnTAL 
EffEcT (Lyg)
IncrEmEnTAL 
EffEcT (QALy) IcEr (€/Lyg) IcEr (€/QALy)
Cohort B
Non-technical 
inoperable
€ 34 285
(€ 29 229 –
 € 38 647)
(0.45 – 1.64) 0.81(-0.30 – 1.77) € 34 301 € 42 285
Cohort B
Technical 
inoperable
€ 36 123
(€ 30 350 – 
€ 41 850)
1.78 (0.60 – 
3.27)
1.36 
(-0.15 – 2.88)
€ 24 270
(€ 11 942 – 
€ 53 898)
€ 26 482
Reference: Belgian Healthcare Knowledge Centre [9]
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of a rate of death from any cause at 1 year 
there was evidence of 20 percentage points 
lower with TAVI than with standard therapy, 
suggesting balloon-expandable TAVI should 
be the new standard of care for patients with 
aortic stenosis who are not suitable candidates 
for surgery [10]. Edwards SAPIEN® valve is 
FDA approved and available for use in the USA 
market and initiated in 2010, the FDA approved 
a randomized controlled trial studying the 
Medtronic CoreValve® which is still ongoing. 
To date, there is no head to head comparison 
between the different percutaneous valves.  
conclusIons
In conclusion, this systematic review 
followed the methodology recommended 
by PRISMA to objectively assess the cost 
effectiveness of TAVI compared with AVR and 
medical management. Although, it is largely 
based on the patient outcome results achieve 
in the PARTNER trial whereby this systematic 
review suggests greater cost effectiveness 
benefit in Cohort B. According to Leon et al., 
additional randomized trials are needed to 
compare TAVI with aortic-valve replacement 
among high-risk patients with aortic stenosis 
for whom surgery is a viable option and 
among low-risk patients with aortic stenosis 
[10]. As seen from the results in Cohort A of 
the PARTNER trial, the smaller the difference 
between incremental cost effectiveness in life 
years gained and quality adjusted life years 
the more you need to perform an RCT to 
illustrate superiority. In view of scarcity of 
resources, cost effectiveness research is needed 
with improved standardization to aggregated 
and disaggregated cost effectiveness endpoints 
allowing for transparency to itemized costs 
and accountability for variations to costs across 
hospitals, countries and health systems. It 
could be argued the major attraction of TAVI 
relates to the benefits of a shorter hospital 
stay and recovery, but this is not incorporated 
into the model [1]. The type of economic 
evaluation and what this entails should be 
clearly stated to accurately compare across 
studies. Combined with limited objective data 
available at present it proved to be challenging 
when attempting to make direct comparisons. 
Given the projected life expectancy of an 
83 year old in the US is roughly 7 years, 
the scope of this systematic review suggests 
a start to further comprehensive analyses. 
In that direction researchers should improve 
the production of high-quality economical 
evaluation studies, which is the assumption to 
better support the decision-making process.
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